KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) EBIAT (2016 - 2026)

TherapeuticsMD filings provide 17 years of EBIAT readings, the most recent being $103000.0 for Q1 2026.

  • On a quarterly basis, EBIAT rose 115.77% to $103000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $1000.0, a 100.05% increase, with the full-year FY2025 number at -$653000.0, up 70.06% from a year prior.
  • EBIAT hit $103000.0 in Q1 2026 for TherapeuticsMD, up from -$703000.0 in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $112.3 million in Q2 2022 to a low of -$49.0 million in Q1 2022.
  • Median EBIAT over the past 5 years was -$703000.0 (2025), compared with a mean of -$439941.2.
  • Biggest five-year swings in EBIAT: skyrocketed 363.25% in 2022 and later plummeted 386.94% in 2025.
  • TherapeuticsMD's EBIAT stood at -$33.2 million in 2022, then surged by 105.11% to $1.7 million in 2023, then tumbled by 85.55% to $245000.0 in 2024, then plummeted by 386.94% to -$703000.0 in 2025, then surged by 114.65% to $103000.0 in 2026.
  • The last three reported values for EBIAT were $103000.0 (Q1 2026), -$703000.0 (Q4 2025), and $50000.0 (Q3 2025) per Business Quant data.